Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 286-298

  Krishna, Gopal ^a   Moton, Allen ^a   Ma, Lei ^a   Savant, Ishani ^a   Martinho, Monika ^a   Seiberling, Michael ^b   McLeod, James ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Swiss Pharma Contract Ltd   (Switzerland)

Author keywords

CYP3A4; drug interactions; midazolam; pharmacokinetics; posaconazole

Indexed keywords

KETOCONAZOLE; MIDAZOLAM; POSACONAZOLE;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG ERUPTION; DRUG TOLERABILITY; DRY SKIN; ELECTROCARDIOGRAPHY; ETHNICITY; FATIGUE; FEMALE; FLATULENCE; HEART PALPITATION; HUMAN; HUMAN EXPERIMENT; INTERVIEW; LIVER PAIN; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SKIN EXFOLIATION; SWITZERLAND; UPPER ABDOMINAL PAIN; VITAL SIGN; VOLUNTEER; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; KETOCONAZOLE; MALE; MIDAZOLAM; MIDDLE AGED; TRIAZOLES;

EID: 62149127834     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.022     Document Type: Article

References (27)

1. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease [published correction appears in N Engl J Med. 2007;357:428]. N Engl J Med 356 (2007) 335-347
2. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
3. Raad I.I., Hachem R.Y., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42 (2006) 1398-1403
4. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 44 (2007) 2-12
5. Ullmann A.J., Cornely O.A., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 (2006) 658-666
6. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases [published correction appears in Clin Infect Dis. 2006;43:1376]. Clin Infect Dis 42 (2006) e61-e65
7. Sabatelli F., Patel R., Mann P.A., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
8. Groll A.H., and Walsh T.J. Posaconazole: Clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 3 (2005) 467-487
9. Wexler D., Courtney R., Richards W., et al. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way cross-over study. Eur J Pharm Sci 21 (2004) 645-653
10. Noxafil [package insert] (2006), Schering Corporation, Kenil-worth, NJ
11. Krieter P., Flannery B., Musick T., et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 48 (2004) 3543-3551
12. Kronbach T., Mathys D., Umeno M., et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36 (1989) 89-96
13. Allonen H., Ziegler G., and Klotz U. Midazolam kinetics. Clin Pharmacol Ther 30 (1981) 653-661
14. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55 (1994) 481-485
15. Ahonen J., Olkkola K.T., and Neuvonen P.J. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40 (1995) 270-272
16. Saari T.I., Laine K., Leino K., et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79 (2006) 362-370
17. Olkkola K.T., Ahonen J., and Neuvonen P.J. The effect of the systemic anti-mycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82 (1996) 511-516
18. Guengerich F.P. Role of cytochrome P450 enzymes in drug-ddrug interactions. Adv Pharmacol 43 (1997) 7-35
19. International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(RR1). International Conference on Harmonisation Steering Committee (1996) 11-53. http://www.iich.org/LOB/mmedia/MEDIA482.pdf E6(RR1). Accessed September 19, 2008
20. Shen J.X., Krishna G., and Hayes R.N. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 43 (2007) 228-236
21. National Cancer Institute.Common terminology criteria for adverse events v3.00 (CCTCAE). National Cancer Institute. 1-72
22. http://cctep.cancer.gov/reporting/cctc_v30.html Accessed November 13, 2007
23. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed (1982), Marcel Dekker, New York, NY
24. Paine M.F., Shen D.D., Kunze K.L., et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60 (1996) 14-24
25. Pichard L., Fabre I., Fabre G., et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-44 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18 (1990) 595-606
26. Back D.J., and Tjia J.F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32 (1991) 624-626
27. DT Y., Peterson J.F., Seger D.L., et al. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 14 (2005) 755-767